Adults with diabetes or obesity using semaglutide may have an increased risk for nonarteritic anterior ischemic optic neuropathy, a common form of optic neuropathy, according to data published in JAMA Ophthalmology.
Nonarteritic anterior ischemic optic neuropathy (NAION) is a form of optic neuropathy that can cause blindness among adults. In a single-center retrospective study of neuro-ophthalmic patients, adults prescribed semaglutide (Ozempic/Wegovy, Novo Nordisk) for the treatment of type 2 diabetes or obesity had higher rates of NAION during a follow-up of 3 years compared with adults